Lonza Group AG

Chart & Performance

D1W1MN

No data to show

P/E

58.82

P/S

5.69

EPS

9.04

Div Yield, %

0.74%

Shrs. gr., 5y

-0.89%

Rev. gr., 5y

9.34%

Revenues

6.57b

-2.13%

Net income

636m

-2.75%

CFO

1.27b

-8.21%

Dividend

May 13, 20250 CHF/sh

Earnings

May 08, 2025

Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.

URL

https://www.lonza.com/

IPO date

Apr 03, 2002

Employees

17,896

Domiciled in

Incorporated in

Valuation

Order:

Title CHF in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CHF in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	6,574,000 -2.13%	6,717,000 7.94%	6,223,000 15.05%
Cost of revenue	5,477,000	5,711,000	4,983,000
Unusual Expense (Income)
NOPBT	1,097,000	1,006,000	1,240,000
NOPBT Margin	16.69%	14.98%	19.93%
Operating Taxes	117,000	135,000	230,000
Tax Rate	10.67%	13.42%	18.55%
NOPAT	980,000	871,000	1,010,000
Net income	636,000 -2.75%	654,000 -46.17%	1,215,000 -58.73%
Dividends	(288,000)	(260,000)	(223,000)
Dividend yield	0.75%	1.00%	0.66%
Proceeds from repurchase of equity	(760,000)	(1,011,000)	(51,000)
BB yield	1.99%	3.88%	0.15%
Debt
Debt current	468,000	227,000	732,000
Long-term debt	4,242,000	3,236,000	1,855,000
Deferred revenue		658,000	739,000
Other long-term liabilities	2,031,000	519,000	762,000
Net debt	2,999,000	1,490,000	65,000
Cash flow
Cash from operating activities	1,274,000	1,388,000	1,039,000
CAPEX	(1,417,000)	(1,682,000)	(1,872,000)
Cash from investing activities	(2,916,000)	(1,096,000)	(991,000)
Cash from financing activities	1,283,000	(152,000)	(286,000)
FCF	(871,000)	696,000	(958,000)
Balance
Cash	1,711,000	1,668,000	2,224,000
Long term investments		305,000	298,000
Excess cash	1,382,300	1,637,150	2,210,850
Stockholders' equity	9,623,000	8,118,000	8,197,000
Invested Capital	14,746,700	12,183,850	12,138,150
ROIC	7.28%	7.16%	8.94%
ROCE	6.60%	7.03%	8.21%
EV
Common stock shares outstanding	71,300	73,684	74,357
Price	535.80 51.48%	353.70 -21.94%	453.10 -40.51%
Market cap	38,202,780 46.58%	26,061,969 -22.64%	33,691,309 -40.61%
EV	41,261,780	27,611,969	33,824,309
EBITDA	1,097,000	1,627,000	1,836,000
EV/EBITDA	37.61	16.97	18.42
Interest	140,000	93,000	73,000
Interest/NOPBT	12.76%	9.24%	5.89%